News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aesica Recruits Operations Director in Formulated Products Business Unit



2/5/2013 7:53:39 AM

5th February 2013 - Newcastle: Aesica, the global contract manufacturing organisation (CMO), has appointed Jarrett Palmer as Operations Director of its formulated products business unit business. Palmer has accumulated over 15 years’ experience in senior leadership positions and has managed facilities for global CMOs including Catalent Pharma Solutions and Piramal Healthcare.

Based at Aesica headquarters in Newcastle (UK), Palmer will report to Chris Gowland , Managing Director of Formulated Products. Operations at the Queenborough facility (UK) and recently acquired sites in Europe - including Monheim and Zwickau (Germany) and Pianezza (Italy) - will be managed by Palmer who will coordinate operational activities around the company’s commercial scale manufacturing, packaging and distribution activities. Pivotal to this new role is the continued sustainable growth of Aesica, which includes continuous improvement to drive manufacturing efficiency and managing growing demand for potent manufacturing from the company’s UK base.

“We are delighted to have Jarrett Palmer join Aesica as Operations Director. He brings significant experience with a long and established track record of managing sites for global CMOs. Jarrett’s role is central to the maintenance of high standards at our FDA approved commercial scale manufacturing sites. He will be critical to the acquisition process and will support senior management in identifying global acquisition targets and transitioning new sites in line with our exacting efficiency and quality standards”, commented Chris Gowland Managing Director of Formulated Products at Aesica.

“Aesica is one of the most exciting names in contract manufacturing at the moment”, added Palmer on his decision to join the company. “It has big plans for growth which will significantly increase its global footprint and its manufacturing and packaging capacity at commercial scale, which is what the market has a great demand for. The prospect of being at the heart of this dynamic business is what attracted me to Aesica. My goal is to ensure that at every step, we optimise our internal infrastructure so that our customers enjoy responsiveness and efficiency in all interaction with us.”

About Aesica:

Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.

The uniqueness of Aesica lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. It is this all-encompassing offering combined with its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.

• Aesica is one of the UK’s fastest growing companies and over the last five years has more than trebled its turnover.

• The company currently employs approximately 1,300 people.

• In addition to its headquarters in Newcastle upon Tyne, UK, Aesica has development and manufacturing sites across Europe including Cramlington, Nottingham and Queenborough in the UK, as well as sites in Monheim and Zwickau in Germany and Pianezza in Italy. It also has sales representation in San Diego and Shanghai.

• The vision of Aesica is to become the number one supplier of APIs and formulated products to the pharmaceutical industry.

For media enquiries, please contact Alex Heeley or Tristan Jervis at De Facto Communications on: +44 (0) 207 861 3019 or +44 (0) 207 861 3043 or e-mail; t.jervis@defacto.com.


Read at BioSpace.com


comments powered by Disqus
Aesica
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES